- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05365659
IKS03 bei Patienten mit fortgeschrittenem B-Zell-Non-Hodgkin-Lymphom
Eine Phase-1-Kohorten-Dosiseskalations- und Expansionsstudie zur Bestimmung der Sicherheit, Verträglichkeit, maximal tolerierten Dosis und vorläufigen antineoplastischen Aktivität von IKS03 bei Patienten mit fortgeschrittenem B-Zell-Non-Hodgkin-Lymphom (NHL)
This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The study will consist of 2 parts: dose-escalation (Part I) and dose-expansion (Part II). The dose-escalation part (Part I) of the study is to evaluate the safety and tolerability of increasing dose levels of IKS03 to establish a recommended Phase 2 dose (RP2D); and the dose-expansion part (Part II) of the study is to further evaluate the safety, pharmacokinetics/pharmacodynamics, and efficacy of IKS03 at the RP2D.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
- Name: David Browning
- Telefonnummer: 615-975-7776
- E-Mail: david.browning@iksuda.com
Studienorte
-
-
New South Wales
-
Westmead, New South Wales, Australien, 2145
- Rekrutierung
- Westmead Hospital
-
Hauptermittler:
- Amanda Johnston, MD
-
-
South Australia
-
Adelaide, South Australia, Australien
- Rekrutierung
- Royal Adelaide Hospital
-
Kontakt:
- Pratyush Giri, MBBS
-
Hauptermittler:
- Pratyush Giri, MBBS
-
-
Tasmania
-
Hobart, Tasmania, Australien, 7000
- Rekrutierung
- Royal Hobart Hospital
-
Hauptermittler:
- Rosemary Harrup, MD
-
-
Western Australia
-
Perth, Western Australia, Australien
- Rekrutierung
- Linear Clinical Research
-
Kontakt:
- Katharine Lewis, MD
-
Hauptermittler:
- Katharine Lewis, MD
-
-
-
-
-
Candiolo, Italien
- Rekrutierung
- Istituto Nazionale Oncologico Candiolo
-
Kontakt:
- Umberto Vitolo, M.D.
-
Hauptermittler:
- Umberto Vitolo, M.D.
-
Milan, Italien
- Rekrutierung
- Istituto Europeo di Oncologia
-
Kontakt:
- Enrico Derenzini, M.D.
-
Hauptermittler:
- Enrico Derenzini, M.D.
-
Milan, Italien
- Rekrutierung
- Istituto Europeo Clinico Humanitas
-
Kontakt:
- Carmelo Carlo-Stella, M.D.
-
Hauptermittler:
- Carmelo Carlo-Stella, M.D.
-
Milan, Italien
- Rekrutierung
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele
-
Kontakt:
- Andres Jose Maria Ferreri, M.D.
-
Hauptermittler:
- Andres Jose Maria Ferreri, M.D.
-
-
-
-
Quebec
-
Montreal, Quebec, Kanada, H3T 1E2
- Rekrutierung
- Jewish General Hospital
-
Hauptermittler:
- Sarit Assouline, MD
-
Kontakt:
- Sarit Assouline, MD
-
-
-
-
-
Badalona, Spanien
- Rekrutierung
- Institut Catala D'Oncologia
-
Kontakt:
- Mireia Franch-Sarto, M.D.
-
Hauptermittler:
- Mireia Franch-Sarto, M.D.
-
Madrid, Spanien
- Rekrutierung
- Hospital Universitario Quironsalud Madrid
-
Kontakt:
- Maria del Carmen Martinez-Chamorro, M.D.
-
Hauptermittler:
- Maria del Carmen Martinez-Chamorro, M.D.
-
Salamanca, Spanien
- Rekrutierung
- Hospital Clinico Universitario de Salamanca
-
Kontakt:
- Alejandro Martin Garcia-Sancho, M.D.
-
Hauptermittler:
- Alejandro Martin Garcia-Sancho, M.D.
-
-
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21201
- Zurückgezogen
- University of Maryland Baltimore
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Males or females, ≥ 18 years of age
-
Part I: documented B cell NHL (any subtype except Burkitt lymphoma, Waldenström macroglobulinemia, chronic lymphocytic leukemia); previously confirmed CD19-positive if feasible
-
Part II: documented B cell NHL (subtypes to be determined); confirmed CD19-positive; possible expansion cohorts may include:
- Diffuse large B cell lymphoma (including germinal center B cell type, activated B cell type)
- Follicular lymphoma (including duodenal-type follicular lymphoma)
- Mantle cell lymphoma
- B cell lymphomas not specified
-
If B cell NHL subtype likely to have bone marrow involvement must be willing to undergo bone marrow biopsy in the event of an on-study complete response to confirm response
-
NHL that is relapsed, refractory to, or intolerant of existing therapy(ies) with known curative potential, or for which no standard therapy is available; must have received at least 2 prior lines of systemic therapy
-
Must be in need of systemic treatment and not require immediate cytoreductive therapy
-
Part I: measurable or non-measurable disease
-
Part II: measurable disease according to The Revised Criteria/Lugano Classification
-
Part I: screening tumor biopsy requested, but optional; Part 2: patient must agree to screening tumor biopsy
-
ECOG performance status 0 or 1
-
Women of childbearing potential and fertile men agreeing to use two effective methods of contraception (including a highly effective method of contraception); women beginning 2 weeks prior to the first dose, men beginning prior to the first dose, and both continuing until 8 months after the last dose of study drug; male patients must also agree to refrain from sperm donation during this period.
-
Ability to understand and give written informed consent
Exclusion Criteria:
-
Women who are pregnant or intending to become pregnant before, during, or within 8 months after the last dose of study drug; women who are breastfeeding
-
Patients documented to be CD19-negative
-
Central nervous system (CNS) lymphoma, leptomeningeal infiltration, or spinal cord compression not controlled by prior surgery or radiotherapy; symptoms suggesting CNS involvement
-
Part 2: History of another malignancy within 2 years, with the exception of:
- Treated, non-melanoma skin cancers
- Treated carcinoma in situ (e.g., breast, cervix)
- Controlled, superficial carcinoma of the urinary bladder
- T1a or b prostate carcinoma treated according to standard of care, with PSA within normal limits
- Papillary thyroid carcinoma Stage I treated surgically for cure
-
Any of the following hematologic abnormalities at baseline (transfusion allowed > 5 days previous):
- Hemoglobin < 8.0 g/dL
- Absolute neutrophil count < 1,000 per mm3
- Platelet count < 75,000 per mm3
-
Any of the following laboratory abnormalities at baseline:
- Total bilirubin > 1.5 × upper limit of normal (ULN); > 3 × ULN if with Gilbert's Syndrome
- AST or ALT > 3 × ULN; > 5 × ULN if due to hepatic involvement by tumor
- Estimated GFR ≤ 60 mL/min corrected for BSA
- Albuminuria defined as urine albumin to creatinine ratio < 30 mg/g or < 3 mg/mmol) by spot urine albumin
-
Any of the following coagulation parameter abnormalities at baseline unless on a stable dose of anticoagulant therapy for a prior thrombotic event:
- PT or INR > 1.5 × ULN; > 3× ULN if anticoagulated)
- PTT > 1.5 × ULN; > 3× ULN if anticoagulated
-
Any of the following laboratory abnormalities at baseline aimed at assessing renal function:
- Estimated glomerular filtration rate (eGFR) ≤ 60 mL/min, corrected for BSA.
- Albuminuria defined as urine albumin to creatinine ratio (UACR) ≥ 45 mg/g or ≥ 4.5 mg/mmol by spot urine albumin
-
Patients with:
- Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 4 weeks unless adequately treated and stable
- Active uncontrolled bleeding or a known bleeding diathesis
-
Significant cardiovascular disease or condition, including:
- Congestive heart failure or angina pectoris requiring therapy
- Ventricular arrhythmia requiring therapy or other uncontrolled arrhythmia
- Severe conduction disturbance (e.g., 3rd degree heart block)
- QTc interval ≥ 480 milliseconds
- Left ventricular ejection fraction below the lower limit of normal or < 50% by MUGA scan or echocardiogram
- Class III or IV cardiovascular disease according to the New York Heart Association Functional Classification
- History of acute coronary syndromes (e.g., MI, unstable angina), coronary angioplasty, stenting, or bypass within 6 months
-
Significant liver disease, including:
- Non-infectious hepatitis
- Hepatic cirrhosis (Child-Pugh Class B and Class C)
-
Significant pulmonary disease or condition, including:
- Significant symptomatic COPD, as assessed by the Investigator
- History or any current evidence on imaging studies of interstitial lung disease, pulmonary fibrosis
- History of pulmonary inflammatory disease, pneumonitis, ARDS
- History of pneumonia within 1 month
-
Significant corneal disease or condition, including history of or current evidence of keratitis
-
Clinically significant CNS disease or condition including PML, epilepsy, vasculitis, or neurodegenerative disease. Also including TIA or stroke within 6 months
-
Known HIV infection or AIDS
-
Active hepatitis B virus or hepatitis C virus infection
-
Any other serious/active/uncontrolled infection, any infection requiring parenteral antibiotics, or unexplained fever > 38ºC within 2 weeks
-
Autoimmune disease or condition requiring systemic steroids or other immunosuppressive medications
-
Unresolved Grade > 1 AE associated with any prior antineoplastic therapy (except persistent Grade 2 alopecia, peripheral neuropathy, decreased hemoglobin, neutropenia, lymphopenia, hypomagnesemia, and/or endocrine end-organ failure being adequately managed by HRT)
-
Known or suspected hypersensitivity to any of the excipients of formulated study drug
-
Inadequate recovery from a surgical procedure, or a major surgical procedure within 4 weeks
-
Any other serious, life-threatening, or unstable preexisting medical condition, including significant organ system dysfunction, or clinically significant laboratory abnormality(ies)
-
A psychiatric disorder or altered mental status that would preclude understanding of the informed consent process
Drugs and Other Treatments to be Excluded:
-
Receipt of:
- Any CD19-targeted therapy within 4 weeks
- Any tumor vaccine within 6 weeks (must have progressed if previously received)
-
Prior autologous/allogeneic CAR-T therapy if known to be CD19-negative after
-
Any other antineoplastic agent for the primary malignancy without delayed toxicity within 3 weeks or 5 plasma half-lives, whichever is shortest (except nitrosoureas and mitomycin C within 6 weeks)
-
Any other investigational treatments within 3 weeks
-
Drugs known to impair renal function, including:
- NSAIDS within 3 days
- Aminoglycoside antibiotics, amphotericin B, etc. within 1 week
- Bisphosphonates within 1 month
-
Prior solid organ transplant
-
Allogeneic HSCT within 6 months, or:
- If receiving immunosuppression
- If with active evidence of GVHD
-
Autologous hematopoietic stem cell transplantation (HSCT) within 3 months
-
Radiotherapy:
- To target lesions within 4 weeks unless progression of the lesion has been documented
- To non-target lesions within 1 week
-
Live/live-attenuated vaccines against infectious diseases within 4 weeks
-
Immunosuppressive or systemic glucocorticoid therapy (> 10 mg prednisone daily or equivalent) within 2 weeks
-
Prophylactic use of hematopoietic growth factors within 1 week
-
Herbal therapies and supplements within 2 weeks
-
Strong inhibitors of cytochrome P450 within 2 weeks
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Dose Escalation Cohort (Part 1)
Each patient will receive repeat doses (by intravenous (IV) infusions) on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met. |
IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent. |
|
Experimental: Dose Expansion: Diffuse-Large B-Cell Lymphoma Participants
Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met. |
IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent. |
|
Experimental: Dose Expansion: Follicular Cell Lymphoma Participants
Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met. |
IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent. |
|
Experimental: Dose Expansion: Mantle Cell Lymphoma Participants
Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met. |
IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent. |
|
Experimental: Dose Expansion: Other B cell lymphoma (B-NHL not otherwise specified [NOS])
Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met. |
IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Recommended Phase 2 Dose (Part I)
Zeitfenster: Up to 20 months
|
RP2D will be determined using dose limiting toxicities (DLTs) and all other available study data |
Up to 20 months
|
|
Objective Response Rate (Part II)
Zeitfenster: up to 42 months
|
Antineoplastic effects will be assessed by Criteria for Response Assessment: The Lugano Classification (Cheson 2014) |
up to 42 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Evaluation of the immunogenicity of IKS03 (Part I and II)
Zeitfenster: Up to 42 months
|
Occurrence of ADA measured in serum at selected timepoints during the study |
Up to 42 months
|
|
Plasma Concentrations of IKS03 (Part I and II)
Zeitfenster: Up to 42 months
|
Pharmacokinetic profile will be characterized by concentrations of IKS03 |
Up to 42 months
|
|
Determine recommended Phase 2 dose (RP2D) (Part II)
Zeitfenster: Up to 42 months
|
Based on evidence of antitumor activity, acceptable tolerability, evidence of achieving target plasma concentration |
Up to 42 months
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Debra Wood, MD, Iksuda Therapeutics
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Lymphatische Erkrankungen
- Lymphoproliferative Erkrankungen
- Immunproliferative Erkrankungen
- Hämische und lymphatische Krankheiten
- Lymphom
- Lymphom, B-Zell
- Lymphom, große B-Zelle, diffus
- Lymphom, Non-Hodgkin
- Lymphom, follikulär
- Lymphom, Mantelzelle
Andere Studien-ID-Nummern
- IKS03-01
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .